KR2 Eye Drops

Developed by Professor Zhang Kang’s research team. This product is a Class 1 innovative drug, the indications are mainly used for the treatment of wet macular degeneration, diabetic retinopathy, iris neovascularization and corneal neovascularization, and other blinding eye diseases.

Professor Zhang Kang obtained a new structure of the active small molecule compound KR2 through a large number of studies, the mechanism of action is to inhibit vegfr2 activity to inhibit the formation of new blood vessels in the eye, and successfully developed it as an eye drop as an non-invasive treatment. According to the preclinical evaluation of the drug in human clinical trials, the drug is safe and has an obvious therapeutic effect, with potential to greatly reduce the treatment cost of patients and alleviate the painful conditions. At present, the drug has 2 international PCT patents and has been authorized by 8 national patents.